A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
Anything in medical notes suggesting unsuitable in the opinion of the investigator
Eligibility criteria for participation in weight loss arm
The presence of any of the following will preclude participant inclusion:
Known or suspected secondary hypertension
Hypersensitivity to any of the study drugs or excipients
Currently taking drugs likely to have interactions with tirzepatide
Diagnosis of type 1 or type 2 diabetes mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists
Prior or planned surgical, endoscopic and/or device-based therapy treatment for obesity
Self-reported, intentional or unintentional, change in body weight (over \~10%) within \~three months of screening
Known heart failure or clinically significant valvular heart disease
Implanted pacemaker or implantable cardioverter defibrillator (ICD)
Second or third-degree AV block, sino-atrial block, sick sinus syndrome
Known active malignancy including thyroid cancer
Known renal impairment (creatinine \>150µmol/L)
Clinically significant neurological disease
History of scleroderma
Participants on anticoagulant therapy
Known history of pancreatitis
Known inflammatory bowel disease
History of gallstones (unless previous cholecystectomy)
Severe gastroparesis or gastric emptying abnormality
Family history of multiple endocrine neoplasia
Needle-phobia
Planned pregnancy, current pregnancy, or breastfeeding
Current involvement in the active treatment phase of other research studies
Any other clinical reason which may preclude entry in the opinion of the investigator
Clareo Health | A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
